SG11201805048SA - Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia - Google Patents
Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemiaInfo
- Publication number
- SG11201805048SA SG11201805048SA SG11201805048SA SG11201805048SA SG11201805048SA SG 11201805048S A SG11201805048S A SG 11201805048SA SG 11201805048S A SG11201805048S A SG 11201805048SA SG 11201805048S A SG11201805048S A SG 11201805048SA SG 11201805048S A SG11201805048S A SG 11201805048SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- data
- lymphoblastic leukemia
- acute lymphoblastic
- pct
- Prior art date
Links
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 title abstract 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 title abstract 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 title abstract 3
- 241000699670 Mus sp. Species 0.000 abstract 3
- 238000000540 analysis of variance Methods 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000002131 composite material Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000007492 two-way ANOVA Methods 0.000 abstract 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000897276 Termes Species 0.000 abstract 1
- 230000005584 early death Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000010149 post-hoc-test Methods 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270749P | 2015-12-22 | 2015-12-22 | |
| US201662306031P | 2016-03-09 | 2016-03-09 | |
| PCT/US2016/068003 WO2017112762A1 (en) | 2015-12-22 | 2016-12-21 | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805048SA true SG11201805048SA (en) | 2018-07-30 |
Family
ID=57799832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805048SA SG11201805048SA (en) | 2015-12-22 | 2016-12-21 | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170174781A1 (es) |
| EP (1) | EP3394102A1 (es) |
| JP (1) | JP2019503363A (es) |
| KR (1) | KR20180087401A (es) |
| CN (1) | CN108602889A (es) |
| AU (1) | AU2016378573A1 (es) |
| BR (1) | BR112018012929A2 (es) |
| CA (1) | CA3009322A1 (es) |
| EA (1) | EA201891495A1 (es) |
| IL (1) | IL260000A (es) |
| MA (1) | MA44145A (es) |
| MX (1) | MX2018007756A (es) |
| SG (1) | SG11201805048SA (es) |
| WO (1) | WO2017112762A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EP3699198A1 (en) | 2014-11-17 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
| SG11201900201YA (en) | 2016-08-16 | 2019-02-27 | Regeneron Pharma | Methods for quantitating individual antibodies from a mixture |
| SG11201902667UA (en) | 2016-10-25 | 2019-05-30 | Regeneron Pharma | Methods and systems for chromatography data analysis |
| EP3807318A4 (en) * | 2018-06-14 | 2022-03-02 | BioAtla, Inc. | MULTISPECIFIC ANTIBODY CONSTRUCTS |
| TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| US11157011B2 (en) * | 2018-07-30 | 2021-10-26 | Fedex Corporate Services, Inc. | Enhanced systems, apparatus, and methods for improved automated and autonomous operation of logistics ground support equipment |
| JP2021535142A (ja) * | 2018-08-31 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 |
| WO2020092499A1 (en) | 2018-10-31 | 2020-05-07 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| US20200392230A1 (en) * | 2019-05-14 | 2020-12-17 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| CN110563849B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
| CN110498857B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
| CN114206924A (zh) | 2019-12-06 | 2022-03-18 | 瑞泽恩制药公司 | 抗vegf蛋白组合物及其制备方法 |
| TW202135860A (zh) * | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| WO2021245233A1 (en) * | 2020-06-04 | 2021-12-09 | Bioinvent International Ab | Improving antibody tolerabilty associated with intravenous administration |
| CN112062855A (zh) | 2020-08-26 | 2020-12-11 | 康诺亚生物医药科技（成都）有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
| CN114524878A (zh) | 2020-11-23 | 2022-05-24 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| AR127271A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1912675T1 (sl) * | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| NO2918604T3 (es) * | 2008-11-07 | 2018-05-19 | ||
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
-
2016
- 2016-12-21 BR BR112018012929A patent/BR112018012929A2/pt not_active Application Discontinuation
- 2016-12-21 EA EA201891495A patent/EA201891495A1/ru unknown
- 2016-12-21 JP JP2018532790A patent/JP2019503363A/ja active Pending
- 2016-12-21 MX MX2018007756A patent/MX2018007756A/es unknown
- 2016-12-21 SG SG11201805048SA patent/SG11201805048SA/en unknown
- 2016-12-21 KR KR1020187018605A patent/KR20180087401A/ko unknown
- 2016-12-21 EP EP16826554.4A patent/EP3394102A1/en not_active Withdrawn
- 2016-12-21 CA CA3009322A patent/CA3009322A1/en not_active Abandoned
- 2016-12-21 CN CN201680076749.1A patent/CN108602889A/zh active Pending
- 2016-12-21 AU AU2016378573A patent/AU2016378573A1/en not_active Abandoned
- 2016-12-21 US US15/386,443 patent/US20170174781A1/en not_active Abandoned
- 2016-12-21 WO PCT/US2016/068003 patent/WO2017112762A1/en active Application Filing
- 2016-12-21 MA MA044145A patent/MA44145A/fr unknown
-
2018
- 2018-06-13 IL IL260000A patent/IL260000A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018012929A2 (pt) | 2018-12-11 |
| WO2017112762A1 (en) | 2017-06-29 |
| JP2019503363A (ja) | 2019-02-07 |
| MA44145A (fr) | 2018-10-31 |
| US20170174781A1 (en) | 2017-06-22 |
| CA3009322A1 (en) | 2017-06-29 |
| KR20180087401A (ko) | 2018-08-01 |
| MX2018007756A (es) | 2018-08-09 |
| IL260000A (en) | 2018-07-31 |
| AU2016378573A1 (en) | 2018-07-19 |
| EP3394102A1 (en) | 2018-10-31 |
| CN108602889A (zh) | 2018-09-28 |
| EA201891495A1 (ru) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805048SA (en) | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201804765UA (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201810883TA (en) | Combination therapy | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201809554VA (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201804127SA (en) | Ctla4 binders | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof |